Search Within

Steven M Horwitz

Formats
  1. Meeting Abstract (374)
  2. Journal Article (244)
  3. Review (13)
  4. Guidelines (10)
  5. Research Letter (9)
  6. Book Section (6)
  7. Editorial (4)
  8. Correspondence (3)
  9. Miscellaneous (1)
Groups
  1. Center for Hematologic Malignancies (664)
  2. Department of Medicine (664)
  3. Hematologic Malignancies, Division of (664)
  4. Lymphoma (664)
  5. Population Sciences Research Program (664)
  6. Survivorship Research (170)

More Groups

People
  1. Alison Moskowitz (231)
  2. Andrew Zelenetz (166)
  3. Paul Hamlin (137)
  4. Ariela Noy (136)
  5. David Straus (121)
  6. Maria Palomba (109)

More People

Years
  1. 2025 (12)
  2. 2024 (50)
  3. 2023 (41)
  4. 2022 (34)
  5. 2021 (53)
  6. 2020 (52)

More Years

Publications
  1. Blood (255)
  2. Journal of Clinical Oncology (64)
  3. Hematological Oncology (38)
  4. Annals of Oncology (18)
  5. Blood Advances (18)
  6. Leukemia and Lymphoma (18)

More Publications

Publishers
  1. American Society of Hematology (276)
  2. American Society of Clinical Oncology (65)
  3. Wiley Blackwell (55)
  4. Elsevier Inc. (33)
  5. Oxford University Press (25)
  6. Taylor & Francis Group (22)

More Publishers

Results (664)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A comprehensive clinical next generation sequencing-based assay can impact hematopathologic diagnosis in a significant subset of patients with hematologic malignancies
    Meeting Abstract

    Pichardo, J. D.; Feldstein, J. T.; Arcila, M.; Batlevi, C.; Zelenetz, A. D.; Moskowitz, C. H.; Horwitz, S. M.; Tallman, M. S.; Stein, E. M.; Klimek, V. M.; more...
    Blood (2014)

    Fulltext@MSK | Save
  • Dose-adjusted EPOCH plus /- rituximab in older patients with high grade diffuse large B-cell lymphoma, Burkitt and T-cell lymphoma: An effective regimen with acceptable toxicity profile
    Meeting Abstract

    Owens, C. N.; Migliacci, J. C.; Horwitz, S. M.; Matasar, M. J.; Moskowitz, A. J.; Noy, A.; Palomba, M. L.; Portlock, C. S.; Straus, D. J.; Younes, A.; more...
    Blood (2014)

    Fulltext@MSK | Save
  • Duvelisib (IPI-145), a PI3K-δ,γ inhibitor, is clinically active in patients with relapsed/refractory chronic lymphocytic leukemia
    Meeting Abstract

    O'Brien, S.; Patel, M.; Kahl, B. S.; Horwitz, S. M.; Foss, F. M.; Porcu, P.; Sweeney, J.; Allen, K.; Faia, K.; Stern, H. M.; more...
    Blood (2014)

    Fulltext@MSK | Save
  • Safety and early efficacy in an ongoing pilot study of brentuximab vedotin and AVD chemotherapy followed by 30 gray involved-site radiotherapy for newly diagnosed, early stage, unfavorable risk Hodgkin lymphoma
    Meeting Abstract

    Kumar, A.; Yahalom, J.; Schoder, H.; Caron, P.; Drullinsky, P.; Gerecitano, J. F.; Hamilton, A.; Hamlin, P.; Horwitz, S. M.; Jacob, A. G.; more...
    Blood (2014)

    Fulltext@MSK | Save
  • Phase II investigator-initiated study of brentuximab vedotin in mycosis fungoides or Sezary syndrome: Final results show significant clinical activity and suggest correlation with CD30 expression
    Meeting Abstract

    Kim, Y. H.; Tavallaee, M.; Rozati, S.; Sundram, U.; Salva, K.; Wood, G. S.; Li, S.; Krathen, M.; Nagpal, S.; Reddy, S.; more...
    Blood (2014)

    Fulltext@MSK | Save
  • Duvelisib (IPI-145), a phosphoinositide-3-kinase-δ,γ inhibitor, shows activity in patients with relapsed/refractory T-cell lymphoma
    Meeting Abstract

    Horwitz, S. M.; Porcu, P.; Flinn, I.; Kahl, B. S.; Sweeney, J.; Stern, H. M.; Douglas, M.; Allen, K.; Kelly, P.; Foss, F. M.
    Blood (2014)

    Fulltext@MSK | Save
  • Safety and early efficacy analysis of a novel combination of the PARP inhibitor veliparib (ABT-888) plus bendamustine and rituximab in patients with lymphoma
    Meeting Abstract

    Gerecitano, J. F.; Hamlin, P.; Horwitz, S. M.; Matasar, M. J.; Moskowitz, A. J.; Moskowitz, C. H.; Noy, A.; Portlock, C. S.; Palomba, M. L.; Straus, D. J.; more...
    Blood (2014)

    Fulltext@MSK | Save
  • A phase 1 evaluation of duvelisib (IPI-145), a PI3K-δ,γ inhibitor, in patients with relapsed/refractory iNHL
    Meeting Abstract

    Flinn, I.; Oki, Y.; Patel, M.; Horwitz, S. M.; Foss, F. M.; Sweeney, J.; Allen, K.; Douglas, M.; Steelman, L.; Dunbar, J.; more...
    Blood (2014)

    Fulltext@MSK | Save
  • Identification of actionable genomic alterations across different lymphoma histologies using a comprehensive next generation genomic sequencing clinical assay
    Meeting Abstract

    Batlevi, C.; Moskowitz, C. H.; Zelenetz, A. D.; Horwitz, S. M.; Palomba, L.; Gerecitano, J. F.; Copeland, A. R.; Hamlin, P.; Matasar, M. J.; Sauter, C. S.; more...
    Blood (2014)

    Fulltext@MSK | Save
  • Pegfilgrastim for patients with newly diagnosed diffuse large B-cell lymphoma undergoing dose adjusted EPOCH-R: The MSKCC experience
    Meeting Abstract

    Lunning, M. A.; Maragulia, J.; Horwitz, S. M.; Moskowitz, C. H.; Noy, A.; Zelenetz, A. D.
    Clinical Lymphoma, Myeloma and Leukemia (2014)

    Fulltext@MSK | Save